Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion type Assertion NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_head.
- NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion description "[HER-2 is overexpressed in approximately 20% of patients with breast cancer and has been associated with poorer prognosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_provenance.
- NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion evidence source_evidence_literature NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_provenance.
- NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion SIO_000772 18620996 NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_provenance.
- NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion wasDerivedFrom befree-2016 NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_provenance.
- NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_assertion wasGeneratedBy ECO_0000203 NP681683.RAdFPsQ5wCVrjgUEqhS7eGuL5F1EKWTyH-JgXVG26K0g0130_provenance.